213 related articles for article (PubMed ID: 29324805)
21. Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration.
Budimir N; de Haan A; Meijerhof T; Gostick E; Price DA; Huckriede A; Wilschut J
Influenza Other Respir Viruses; 2013 Nov; 7(6):1202-9. PubMed ID: 24102979
[TBL] [Abstract][Full Text] [Related]
22. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
[TBL] [Abstract][Full Text] [Related]
23. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
[TBL] [Abstract][Full Text] [Related]
24. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.
Wang BZ; Xu R; Quan FS; Kang SM; Wang L; Compans RW
PLoS One; 2010 Nov; 5(11):e13972. PubMed ID: 21124769
[TBL] [Abstract][Full Text] [Related]
25. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
[TBL] [Abstract][Full Text] [Related]
26. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
27. CD47 Plays a Role as a Negative Regulator in Inducing Protective Immune Responses to Vaccination against Influenza Virus.
Lee YT; Ko EJ; Lee Y; Lee YN; Bian Z; Liu Y; Kang SM
J Virol; 2016 Aug; 90(15):6746-6758. PubMed ID: 27194758
[TBL] [Abstract][Full Text] [Related]
28. Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination.
Hemann EA; Kang SM; Legge KL
J Immunol; 2013 Sep; 191(5):2486-94. PubMed ID: 23885108
[TBL] [Abstract][Full Text] [Related]
29. Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens.
Song BM; Kang HM; Lee EK; Jung SC; Kim MC; Lee YN; Kang SM; Lee YJ
Vaccine; 2016 Jan; 34(5):678-686. PubMed ID: 26691568
[TBL] [Abstract][Full Text] [Related]
30. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
[TBL] [Abstract][Full Text] [Related]
31. Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.
Mohan T; Kim J; Berman Z; Wang S; Compans RW; Wang BZ
J Control Release; 2016 Jul; 233():208-19. PubMed ID: 27178810
[TBL] [Abstract][Full Text] [Related]
32. M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.
Sarawar S; Hatta Y; Watanabe S; Dias P; Neumann G; Kawaoka Y; Bilsel P
Vaccine; 2016 Sep; 34(42):5090-5098. PubMed ID: 27595896
[TBL] [Abstract][Full Text] [Related]
33. Induction of heterosubtypic immunity to influenza virus by intranasal immunization.
Quan FS; Compans RW; Nguyen HH; Kang SM
J Virol; 2008 Feb; 82(3):1350-9. PubMed ID: 18032492
[TBL] [Abstract][Full Text] [Related]
34. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS
Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578
[TBL] [Abstract][Full Text] [Related]
35. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
[TBL] [Abstract][Full Text] [Related]
36. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
Quan FS; Huang C; Compans RW; Kang SM
J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
[TBL] [Abstract][Full Text] [Related]
37. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
[TBL] [Abstract][Full Text] [Related]
38. Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.
Lee YN; Kim MC; Lee YT; Hwang HS; Lee J; Kim C; Kang SM
PLoS One; 2015; 10(9):e0137822. PubMed ID: 26366729
[TBL] [Abstract][Full Text] [Related]
39. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
40. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
